Edinburgh Research Explorer

Prof John Smyth

(Former employee or visitor)

  1. 2012
  2. Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy

    Storey, D. J., McLaren, D. B., Atkinson, M. A., Butcher, I., Frew, L. C., Smyth, J. F. & Sharpe, M., Jun 2012, In : Annals of oncology. 23, 6, p. 1542-+ 8 p.

    Research output: Contribution to journalArticle

  3. Clinically relevant fatigue in recurrence-free prostate cancer survivors

    Storey, D. J., McLaren, D. B., Atkinson, M. A., Butcher, I., Liggatt, S., O'Dea, R., Smyth, J. F. & Sharpe, M., Jan 2012, In : Annals of oncology. 23, 1, p. 65-72 8 p.

    Research output: Contribution to journalArticle

  4. Association of galectin-3 expression with melanoma progression and prognosis

    Brown, E. R., Doig, T., Anderson, N., Brenn, T., Doherty, V., Xu, Y., Bartlett, J. M. S., Smyth, J. F. & Melton, D. W., 2012, In : European Journal of Cancer. 48, 6, p. 865-74 10 p.

    Research output: Contribution to journalArticle

  5. 2011
  6. Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy

    Storey, D. J., McLaren, D. B., Atkinson, M. A., Butcher, I., Frew, L. C., Smyth, J. F. & Sharpe, M., 1 Nov 2011, In : International Braz J Urol. 37, 6, p. 798 1 p.

    Research output: Contribution to journalArticle

  7. The interface between medical oncology and supportive and palliative cancer care

    Storey, D. J., Fallon, M. T. & Smyth, J. F., 2011, In : Seminars in oncology. 38, 3, p. 337-42 6 p.

    Research output: Contribution to journalArticle

  8. 2010
  9. Higher incidence of isolated brain metastases in ovarian cancer patients with previous early breast cancer

    Faluyi, O. O., Gourley, C., Smyth, J. F., Faratian, D., Williams, A. R., Rye, T., Rye, R., Stewart, M. & Mackean, M. J., Dec 2010, In : International Journal of Gynecological Cancer. 20, 9, p. 1511-7 7 p.

    Research output: Contribution to journalArticle

  10. Investigator-initiated trials of targeted oncology agents: why independent research is at risk?

    Bergmann, L., Berns, B., Dalgleish, A. G., von Euler, M., Hecht, T. T., Lappin, G. L., Reed, N., Palmeri, S., Smyth, J., Embacher-Aichorn, S., Zwierzina, H. & Biotherapy Dev Assoc, Aug 2010, In : Annals of oncology. 21, 8, p. 1573-1578 6 p.

    Research output: Contribution to journalLiterature review

  11. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine

    Dangoor, A., Lorigan, P., Keilholz, U., Schadendorf, D., Harris, A., Ottensmeier, C., Smyth, J., Hoffmann, K., Anderson, R., Cripps, M., Schneider, J. & Hawkins, R., Jun 2010, In : Cancer Immunology, Immunotherapy. 59, 6, p. 863-873 11 p.

    Research output: Contribution to journalArticle

  12. WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis

    Paige, A. J. W., Zucknick, M., Janczar, S., Paul, J., Mein, C. A., Taylor, K. J., Stewart, M., Gourley, C., Richardson, S., Perren, T., Ganesan, T. S., Smyth, J. F., Brown, R. & Gabra, H., Mar 2010, In : European Journal of Cancer. 46, 4, p. 818-825 8 p.

    Research output: Contribution to journalArticle

  13. 2009
  14. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans

    Charles, K. A., Kulbe, H., Soper, R., Escorcio-Correia, M., Lawrence, T., Schultheis, A., Chakravarty, P., Thompson, R. G., Kollias, G., Smyth, J. F., Balkwill, F. R. & Hagemann, T., Oct 2009, In : Journal of Clinical Investigation. 119, 10, p. 3011-3023 13 p.

    Research output: Contribution to journalArticle

  15. What to do after winning the Nobel Prize - Work harder!

    Smyth, J. F., Feb 2009, In : European Journal of Cancer. 45, 3, p. 318-318 1 p.

    Research output: Contribution to journalEditorial

  16. The use of aromatase inhibitors in ovarian cancer and identification of responsive tumors

    Langdon, S., Faratian, D., Gourley, C., Williams, A., Um, I. H., Smyth, J. & Harrison, D., 2009, Aromatase inhibitors: Types, Mode of Action and Indications. Nova Science Pub Incorporated, p. 163-174 (Cancer Etiology, Diagnosis and Treatment Series).

    Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)

  17. WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3

    Gourley, C., Paige, A. J. W., Taylor, K. J., Ward, C., Kuske, B., Zhang, J., Sun, M., Janczar, S., Harrison, D. J., Muir, M., Smyth, J. F. & Gabra, H., 2009, In : Cancer Research. 69, 11, p. 4835-42 8 p.

    Research output: Contribution to journalArticle

  18. 2008
  19. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer

    Brown, E. R., Charles, K. A., Hoare, S. A., Rye, R. L., Jodrell, D. I., Aird, R. E., Vora, R., Prabhakar, U., Nakada, M., Corringham, R. E., DeWitte, M., Sturgeon, C., Propper, D., Balkwill, F. R. & Smyth, J. F., Jul 2008, In : Annals of oncology. 19, 7, p. 1340-1346 7 p.

    Research output: Contribution to journalArticle

  20. Investigation of melanoma progression and identification of novel prognostic markers using comprehensive tissue microarrays

    Brown, E. R. S., Doig, T., Anderson, N., Doherty, V. R., Smyth, J. F. & Melton, D. W., Jul 2008, In : EJC Supplements. 6, 9, p. 154-154 1 p.

    Research output: Contribution to journalMeeting abstract

  21. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors

    Izquierdo, M. A., Bowman, A., Garcia, M., Jodrell, D., Martinez, M., Pardo, B., Gomez, J., Lopez-Martin, J. A., Jimeno, J., Germa, J. R. & Smyth, J. F., 15 May 2008, In : Clinical Cancer Research. 14, 10, p. 3105-3112 8 p.

    Research output: Contribution to journalArticle

  22. Endometrioid epithelial ovarian cancer: 20 years of prospectively collected data from a single center

    Storey, D. J., Rush, R., Stewart, M., Rye, T., Al-Nafussi, A., Williams, A. R., Smyth, J. F. & Gabra, H., May 2008, In : Cancer. 112, 10, p. 2211-20 10 p.

    Research output: Contribution to journalArticle

  23. Terminology: the historical perspective, evolution and current usage - room for confusion?

    Fallon, M. & Smyth, J., May 2008, In : European Journal of Cancer. 44, 8, p. 1069-1071 3 p.

    Research output: Contribution to journalArticle

  24. Disclosing gaps between supportive and palliative care - the past 20 years

    Smyth, J. F., Feb 2008, In : Supportive Care in Cancer. 16, 2, p. 109-111 3 p.

    Research output: Contribution to journalEditorial

  25. The strength of European oncology

    Smyth, J. F., Jan 2008, In : European Journal of Cancer. 44, 1, p. 6-7 2 p.

    Research output: Contribution to journalEditorial

  26. Hormone therapy for epithelial ovarian cancer

    Langdon, S. P. & Smyth, J. F., 2008, In : Current opinion in oncology. 20, 5, p. 548-53 6 p.

    Research output: Contribution to journalLiterature review

  27. 2007
  28. Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer

    Walker, G., MacLeod, K., Williams, A. R. W., Cameron, D. A., Smyth, J. F. & Langdon, S. P., 1 Mar 2007, In : Clinical Cancer Research. 13, 5, p. 1438-44 7 p.

    Research output: Contribution to journalArticle

  29. Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling

    Mullen, P., Cameron, D. A., Hasmann, M., Smyth, J. F. & Langdon, S. P., Jan 2007, In : Molecular Cancer Therapeutics. 6, 1, p. 93-100 8 p.

    Research output: Contribution to journalArticle

  30. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients

    Smyth, J. F., Gourley, C., Walker, G., MacKean, M. J., Stevenson, A., Williams, A. R. W., Al-Nafussi, A., Rye, T., Rye, R., Stewart, M., McCurdy, J., Mano, M., Reed, N., McMahon, T., Vasey, P., Gabra, H. & Langdon, S. P., 2007, In : Clinical Cancer Research. 13, 12, p. 3617-22 6 p.

    Research output: Contribution to journalArticle

  31. Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer

    Walker, G., MacLeod, K., Williams, A. R. W., Cameron, D. A., Smyth, J. F. & Langdon, S. P., 2007, In : Gynecologic Oncology. 106, 3, p. 461-8 8 p.

    Research output: Contribution to journalArticle

  32. Validation of a new prognostic index for advanced epithelial ovarian cancer: results from its application to a UK-based cohort

    Clark, T. G., Stewart, M., Rye, T., Smyth, J. F. & Gourley, C., 2007, In : Journal of Clinical Oncology. 25, 35, p. 5669-70; author reply 5670-1

    Research output: Contribution to journalArticle

  33. 2006
  34. Olivine hydration in the deep upper mantle: Effects of temperature and silica activity

    Smyth, J. R., Frost, D. J., Nestola, F., Holl, C. M. & Bromiley, G., 1 Aug 2006, In : Geophysical Research Letters. 33, 15, 5 p., 15301.

    Research output: Contribution to journalArticle

  35. Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells

    McPhillips, F., Mullen, P., MacLeod, K. G., Sewell, J. M., Monia, B. P., Cameron, D. A., Smyth, J. F. & Langdon, S. P., Apr 2006, In : Carcinogenesis. 27, 4, p. 729-39 11 p.

    Research output: Contribution to journalArticle

  36. Comparison of strategies targeting Raf-1 mRNA in ovarian cancer

    Mullen, P., McPhillips, F., Monia, B. P., Smyth, J. F. & Langdon, S. P., 15 Mar 2006, In : International Journal of Cancer. 118, 6, p. 1565-71 7 p.

    Research output: Contribution to journalArticle

  37. 2005
  38. Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen

    O'Donnell, A. J. M., Macleod, K. G., Burns, D. J., Smyth, J. F. & Langdon, S. P., Dec 2005, In : Endocrine-Related Cancer. 12, 4, p. 851-66 16 p.

    Research output: Contribution to journalArticle

  39. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer

    Macleod, K., Mullen, P., Sewell, J., Rabiasz, G., Lawrie, S., Miller, E., Smyth, J. F. & Langdon, S. P., 1 Aug 2005, In : Cancer Research. 65, 15, p. 6789-800 12 p.

    Research output: Contribution to journalArticle

  40. The mechanism of action of Kahalalide F: variable cell permeability in human hepatoma cell lines

    Sewell, J. M., Mayer, I., Langdon, S. P., Smyth, J. F., Jodrell, D. I. & Guichard, S. M., Jul 2005, In : European journal of cancer (Oxford, England : 1990). 41, 11, p. 1637-44 8 p.

    Research output: Contribution to journalArticle

  41. WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear

    Gourley, C., Paige, A. J. W., Taylor, K. J., Scott, D., Francis, N-J., Rush, R., Aldaz, C. M., Smyth, J. F. & Gabra, H., Jun 2005, In : International journal of oncology. 26, 6, p. 1681-9 9 p.

    Research output: Contribution to journalArticle

  42. Role of TGF alpha stimulation of the ERK, PI3 kinase and PLC gamma pathways in ovarian cancer growth and migration

    Sewell, J. M., Smyth, J. F. & Langdon, S. P., 10 Mar 2005, In : Experimental Cell Research. 304, 1, p. 305-16 12 p.

    Research output: Contribution to journalArticle

  43. 2004
  44. Carcinosarcoma of the ovary: 19 years of prospective data from a single center

    Brown, E., Stewart, M., Rye, T., Al-Nafussi, A., Williams, A. R. W., Bradburn, M., Smyth, J. & Gabra, H., 15 May 2004, In : Cancer. 100, 10, p. 2148-53 6 p.

    Research output: Contribution to journalArticle

  45. Adrenal carcinoma treated with chemotherapy can result in prolonged survival

    Nussey, F., Seckl, J. & Smyth, J., Apr 2004, In : Clinical Oncology. 16, 2, p. 157-158 2 p.

    Research output: Contribution to journalLetter

  46. Antisense oligonucleotide targeting of Raf-1: importance of raf-1 mRNA expression levels and raf-1-dependent signaling in determining growth response in ovarian cancer

    Mullen, P., McPhillips, F., MacLeod, K., Monia, B., Smyth, J. F. & Langdon, S. P., 15 Mar 2004, In : Clinical Cancer Research. 10, 6, p. 2100-8 9 p.

    Research output: Contribution to journalArticle

  47. 2003
  48. Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppression

    Stronach, E. A., Sellar, G. C., Blenkiron, C., Rabiasz, G. J., Taylor, K. J., Miller, E. P., Massie, C. E., Al-Nafussi, A., Smyth, J. F., Porteous, D. J. & Gabra, H., 15 Dec 2003, In : Cancer Research. 63, 24, p. 8648-8655 8 p.

    Research output: Contribution to journalArticle

  49. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer

    Sellar, G. C., Watt, K. P., Rabiasz, G. J., Stronach, E. A., Li, L., Miller, E. P., Massie, C. E., Miller, J., Contreras-Moreira, B., Scott, D., Brown, I., Williams, A., Bates, P. A., Smyth, J. F. & Gabra, H., Jul 2003, In : Nature Genetics. 34, 3, p. 337-43 7 p.

    Research output: Contribution to journalArticle

  50. 2002
  51. Neuregulin expression, function, and signaling in human ovarian cancer cells

    Gilmour, L. M. R., Macleod, K. G., McCaig, A., Sewell, J. M., Gullick, W. J., Smyth, J. F. & Langdon, S. P., Dec 2002, In : Clinical Cancer Research. 8, 12, p. 3933-42 10 p.

    Research output: Contribution to journalArticle

  52. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup

    Bowman, A., Gabra, H., Langdon, S. P., Lessells, A., Stewart, M., Young, A. & Smyth, J. F., Jul 2002, In : Clinical Cancer Research. 8, 7, p. 2233-9 7 p.

    Research output: Contribution to journalArticle

  53. Malignant mixed mesodermal tumours: biology and clinical aspects

    Gourley, C., Al-Nafussi, A., Abdulkader, M., Smyth, J. F. & Gabra, H., Jul 2002, In : European journal of cancer (Oxford, England : 1990). 38, 11, p. 1437-46 10 p.

    Research output: Contribution to journalArticle

  54. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters

    Oberst, M. D., Johnson, M. D., Dickson, R. B., Lin, C-Y., Singh, B., Stewart, M., Williams, A., al-Nafussi, A., Smyth, J. F., Gabra, H. & Sellar, G. C., Apr 2002, In : Clinical Cancer Research. 8, 4, p. 1101-7 7 p.

    Research output: Contribution to journalArticle

  55. Identification of differentially expressed mRNAS associated with chromosome 11 transfer into the ovarian cancer cell line OVCAR3

    Blenkiron, C., Stronach, E. A., Sellar, G. C., Rabiasz, G. J., Miller, E. P., Porteous, D. J., Smyth, J. F. & Gabra, H., 2002, In : British Journal of Cancer. 86, p. S90-S90

    Research output: Contribution to journalArticle

  56. OBCAM, an IgLON cell adhesion molecule from 11q25, is frequently inactivated in sporadic epithelial ovarian cancer

    Sellar, G. C., Watt, K. P., Stronach, E. A., Rabiasz, G. J., Miller, E. P., Massie, C., Scott, D., Porteous, D. J., Smyth, J. F. & Gabra, H., 2002, In : Proceedings of the American Association for Cancer Research Annual Meeting. 43, p. 146 1 p.

    Research output: Contribution to journalArticle

  57. The homeobox gene BARX2 can modulate cisplatin sensitivity in human epithelial ovarian cancer

    Sellar, G. C., Watt, K. P., Li, L., Nelkin, B. D., Rabiasz, G. J., Porteous, D. J., Smyth, J. F. & Gabra, H., 2002, In : International journal of oncology. 21, 5, p. 929-33 5 p.

    Research output: Contribution to journalArticle

  58. 2001
  59. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study

    Cameron, D. A., Cornbleet, M. C., Mackie, R. M., Hunter, J. A., Gore, M., Hancock, B., Smyth, J. F. & Scottish Melanoma Group, 4 May 2001, In : British Journal of Cancer. 84, 9, p. 1146-9 4 p.

    Research output: Contribution to journalArticle

  60. Functional identification of RALDH2 dysregulation by cDNA representational difference analysis in chromosome 11 mediated growth suppression of ovarian cancer

    Blenkiron, C., Sellar, G. C., Stronach, E., Rabiasz, G. J., Miller, E. P., Porteous, D. J., Smyth, J. F. & Gabra, H., 2001, In : British Journal of Cancer. 85, p. 73javascript:void(0); 1 p.

    Research output: Contribution to journalArticle

  61. 1996
  62. A statistical analysis of chromosome 11 and 17 loss of heterozygosity in epithelial ovarian cancer

    Gabra, H., Watson, J., Eccles, D., Taylor, L., Taylor, K., Cohen, B., Leonard, R., Porteous, D., Smyth, J. & Steel, C., 1996, In : International journal of oncology. 8, 3, p. 625-31 7 p.

    Research output: Contribution to journalArticle

Previous 1 2 Next